|
|
News for:
|
|
For this drug, our server compiled this detailed Chemical Profile.
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
|
Click the Chemical Profile link above for detailed information.
Visit Betterchem's Drug Index for
- Exclusivity
Patents and market exclusivity
- Drug Information
Prescribing and other
information
- DMFs
Type 2 drug master files
- Databases
Free access to database search
- 21 CFR
FDA regulations for this drug
- Federal Register
FR search results for this drug
- Drug Recalls
For Rx's using this API
|
|
|
| |
FDA Approval Activities for this Drug
Sandostatin (octreotide acetate for injectable suspension) Depot
10, 20 and 30 mg. Novartis .
NDA 21-008 11/25/98 11/30 12/1 7/4/99
Sandostatin Indication: Reduction of growth hormone and IGF-1 in acromegaly, the suppression of severe diarrhea and flushing associated with malignant carcinoid syndrome and for the treatment of the profuse watery diarrhea associated with VIPoma (vasoactive intestinal peptide tumor).
Sandostatin (octreotide acetate) Injection, Novartis 19-667/S44 1/17/03 1/23/03 1/23/03
Sandostatin (octreotide acetate) Injection, Novartis 19-667/S42 2/10/03 2/12/03
Sandostatin (octreotide acetate) Injection, Novartis 19-667/S28 & S32 Sandostatin LAR Depot (octreotide acetate) Injection, Novartis Pharmaceuticals Sandostatin LAR Depot (octreotide acetate) Injection, Novartis Pharmaceuticals | Sandostatin LAR Depot (octreotide acetate) Injection, Novartis Pharma, Labeling Revision | Octreotide Acetate Injection, Bedford Labs, Approval | Octreotide Acetate Injection, Sicor Pharma, Tentative Approval | Octreotide Acetate Injection, Sicor Pharma, Tentative Approval | Octreotide Acetate Injection, Bedford Labs, Approval | Octreotide Acetate Injection, Bedford Labs, Approval | Sandostatin (octreotide acetate) Injection, Novartis Pharma, Labeling Revision | Octreotide Acetate Injection, Sicor Pharma, Approval | Octreotide Acetate Injection, Sicor Pharma, Approval | Octreotide Acetate Injection, American Pharma, Approval | Octreotide Acetate Injection, American Pharma, Approval | Sandostatin (octreotide acetate for injectable suspension) LAR Depot, Novartis, Patient Population Altered & Labeling Revision
Visit Betterchem's Drug Index for FDA's latest approval information.
|
|